CD8A and neoplasm: This is carried out through (1) a decrease in the production and release of regulatory T cells, TAMs, MDSCs, IL-10, and TGF-β, (2) the enhancement of CD8+ T cell activation in the priming stage by promoting dendritic cell antigen presentation, and (3) the normalization of tumor vasculature to allow the migration of activated T cells to the cancer.